Biotech Stocks Surge in After-Hours Trading on Friday in Anticipation of Important Clinical Trial Announcements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy RAPP?
Source: NASDAQ.COM
MBX Biosciences Surge: MBX Biosciences Inc. saw a 33% increase in after-hours trading, driven by anticipation of topline results from its Phase 2 trial of Canvuparatide for chronic hypoparathyroidism, scheduled for release on September 22.
Structure Therapeutics Growth: Structure Therapeutics Inc. experienced an 11.37% rise in after-hours trading, fueled by interest in its lead candidate aleniglipron, currently in Phase 2b trials for obesity, with topline results expected by the end of 2025.
Cartesian Therapeutics Update: Cartesian Therapeutics Inc. gained 5.51% in after-hours trading, with preliminary data from its Phase 2 trial of Descartes-08 for systemic lupus erythematosus expected in late 2025, while maintaining sufficient cash reserves to support operations through mid-2027.
Rapport and Rezolute Movements: Rapport Therapeutics Inc. rose 3.60% following positive Phase 2a trial results for RAP-219, while Rezolute Inc. increased 3.77% after reporting fiscal results and confirming upcoming topline data from its Phase 3 trial for congenital hyperinsulinism expected in December 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.140
Low
40.00
Averages
54.60
High
80.00
Current: 37.140
Low
40.00
Averages
54.60
High
80.00
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
- Significant Clinical Efficacy: Rapport Therapeutics' RAP-219 achieved a 90% median reduction in seizures during the first four weeks of follow-up after an eight-week treatment, indicating its clinical significance and potential market value in treating epilepsy.
- Robust Study Results: In a study involving 30 adults with drug-resistant focal onset seizures, RAP-219's long half-life of approximately 22 days allowed for a 90% median reduction in seizures during weeks 9-12 post-treatment, with a sustained 59% reduction in weeks 13-16, demonstrating its ability to maintain seizure control.
- Good Safety Profile: RAP-219 was generally well tolerated with only mild treatment-related side effects reported; serious adverse events occurred but were deemed unrelated to the drug by investigators, enhancing its feasibility for clinical use.
- Future Development Plans: Rapport plans to initiate two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, in the second quarter of 2026 to further evaluate RAP-219 for focal onset seizures, while also conducting a Phase 2 trial for bipolar mania, showcasing the company's broad strategy in neurological disorders.
See More
Form 144: Rapport Therapeutics (RAPP.US) 10% Stakeholder Plans to Sell $17.18 Million in Common Shares
- Stock Sale Announcement: Third Rock Ventures, L.P. plans to sell 426,001 shares of its common stock on April 17, 2023.
- Market Value: The total market value of the shares being sold is approximately $17.18 million.
See More
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Company Performance: The therapeutics company reported a 5% increase in shares, indicating positive market response.
Grant Approval: The company has received grants in China aimed at supporting the development of epilepsy drugs.
See More
Rapport Partners with Tenacia for RAP-219 Development in Greater China
- Partnership Highlights: Rapport Therapeutics has partnered with Tenacia Biotechnology, granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, covering indications such as epilepsy and bipolar disorder, which is expected to accelerate the global development of the drug.
- Financial Gains: Under the agreement, Rapport will receive an upfront payment of $20 million and has the potential to earn up to $308 million in development and commercialization milestone payments, along with tiered royalties, significantly enhancing the company's financial position.
- Clinical Trial Plans: RAP-219 demonstrated significant efficacy in a Phase 2 trial for drug-resistant epilepsy, with a Phase 3 trial expected to initiate in Q2 2026, further validating its potential in epilepsy treatment.
- Market Demand: Tenacia's regional expertise will expand the global reach of RAP-219, addressing the urgent need for innovative treatments for epilepsy and bipolar disorder in Greater China, facilitating faster patient access to this potential best-in-class therapy.
See More
Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
- Significant Clinical Efficacy: Rapport Therapeutics' RAP-219 achieved a 90% median reduction in seizures during the first four weeks of follow-up after an eight-week treatment, indicating its clinical significance and potential market value in treating epilepsy.
- Robust Study Results: In a study involving 30 adults with drug-resistant focal onset seizures, RAP-219's long half-life of approximately 22 days allowed for a 90% median reduction in seizures during weeks 9-12 post-treatment, with a sustained 59% reduction in weeks 13-16, demonstrating its ability to maintain seizure control.
- Good Safety Profile: RAP-219 was generally well tolerated with only mild treatment-related side effects reported; serious adverse events occurred but were deemed unrelated to the drug by investigators, enhancing its feasibility for clinical use.
- Future Development Plans: Rapport plans to initiate two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, in the second quarter of 2026 to further evaluate RAP-219 for focal onset seizures, while also conducting a Phase 2 trial for bipolar mania, showcasing the company's broad strategy in neurological disorders.
See More
Form 144: Rapport Therapeutics (RAPP.US) 10% Stakeholder Plans to Sell $17.18 Million in Common Shares
- Stock Sale Announcement: Third Rock Ventures, L.P. plans to sell 426,001 shares of its common stock on April 17, 2023.
- Market Value: The total market value of the shares being sold is approximately $17.18 million.
See More
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Company Performance: The therapeutics company reported a 5% increase in shares, indicating positive market response.
Grant Approval: The company has received grants in China aimed at supporting the development of epilepsy drugs.
See More
Rapport Partners with Tenacia for RAP-219 Development in Greater China
- Partnership Highlights: Rapport Therapeutics has partnered with Tenacia Biotechnology, granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, covering indications such as epilepsy and bipolar disorder, which is expected to accelerate the global development of the drug.
- Financial Gains: Under the agreement, Rapport will receive an upfront payment of $20 million and has the potential to earn up to $308 million in development and commercialization milestone payments, along with tiered royalties, significantly enhancing the company's financial position.
- Clinical Trial Plans: RAP-219 demonstrated significant efficacy in a Phase 2 trial for drug-resistant epilepsy, with a Phase 3 trial expected to initiate in Q2 2026, further validating its potential in epilepsy treatment.
- Market Demand: Tenacia's regional expertise will expand the global reach of RAP-219, addressing the urgent need for innovative treatments for epilepsy and bipolar disorder in Greater China, facilitating faster patient access to this potential best-in-class therapy.
See More
